Synopsis
Anticipate, distinguish and manage prolonged postoperative mineral uptake after parathyroid surgery while protecting against acute symptomatic hypocalcaemia.
- Hungry-bone syndrome is sustained postoperative hypocalcaemia caused by rapid skeletal uptake of calcium, phosphate and magnesium after an abrupt fall in excessive parathyroid hormone drive.
- Risk is greatest with severe longstanding hyperparathyroid bone turnover, high alkaline phosphatase, radiological bone disease, very high preoperative PTH, vitamin D deficiency and extensive parathyroid surgery.
- The biochemical pattern often combines low calcium, low phosphate and low magnesium with a PTH concentration that is not appropriately absent; postoperative hypoparathyroidism more typically produces low calcium with high phosphate and low or inappropriately normal PTH.
Key red flags
Perioral or fingertip tingling, muscle aching, cramps and heightened reflexes may precede overt tetany and should trigger an immediate calcium check after surgery.
Investigation priorities
Confirm severity and define the postoperative direction and response to replacement.
Management branches
A patient with marked primary or renal hyperparathyroidism is scheduled for parathyroid surgery.
- Identify high bone-turnover features, renal impairment, vitamin D and magnesium deficiency, previous fractures and medicines that complicate calcium interpretation or replacement.
- Agree the postoperative calcium, phosphate, magnesium and PTH schedule with endocrine, renal and surgical teams, including the monitored setting and access to intravenous calcium.
Calcium is clinically stable on an oral regimen and the patient can manage treatment outside hospital.
Key medicines
Calcium gluconate 10% for acute symptomsFor acute symptomatic hypocalcaemia, the current SmPC permits 10–20 mL by slow intravenous injection or diluted infusion over 10 minutes with plasma calcium and ECG monitoring; repeat and continuing infusion decisions require the live protocol and senior review.
Oral calcium with active vitamin DDose and divide the locally selected calcium preparation and calcitriol or alfacalcidol individually under endocrine or renal supervision, titrating to serial biochemistry rather than applying a fixed universal hungry-bone regimen.